Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases.

Abstract

BACKGROUND:

Dyslipidemia is commonly observed in polycystic ovary syndrome (PCOS) patients. Bezafibrate is a drug for dyslipidemia acting through peroxisome proliferator-activated receptors. We investigated the effects of bezafibrate for ovulation induction in patients with PCOS with dyslipidemia who were resistant to clomiphene citrate (CC).

METHODS:

This was a prospective pilot study. Seven infertile, CC-resistant, PCOS patients with dyslipidemia were enrolled in this study. The participants received bezafibrate at 400 mg/day from day 1 of menses and CC at 100 mg/day from day 5 of menses simultaneously until one follicle measuring at least 18 mm in diameter was found by transvaginal ultrasound. The main outcome was ovulation rate.

RESULTS:

Five of 7 patients successfully ovulated. The mean number of days of menses until the follicle reached 18 mm in diameter was 16 ± 3 (range 13-20). Monofollicular development was observed in all patients that ovulated. One woman became pregnant and delivered a healthy baby.

CONCLUSION:

Bezafibrate may be effective for ovulation induction in CC-resistant PCOS patients with dyslipidemia.

• Authors: Shuichiro Hara, Toshifumi Takahashi, Mitsuyoshi Amita, Hideki Igarashi, Hirohisa Kurachi
• Journal: Gynecologic and obstetric investigation (Gynecol Obstet Invest) Vol. 70 Issue 3 Pg. 166-72 ( 2010) ISSN: 1423-002X [Electronic] Switzerland
• PMID: 20558990 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2010 S. Karger AG, Basel.

Chemical References

• Fertility Agents, Female
• Hypolipidemic Agents
• Clomiphene
• Bezafibrate

Topics

• Adult
• Bezafibrate (therapeutic use)
• Clomiphene (therapeutic use)
• Drug Resistance
• Drug Therapy, Combination
• Dyslipidemias (drug therapy)
• Female
• Fertility Agents, Female (therapeutic use)
• Humans
• Hypolipidemic Agents (therapeutic use)
• Infertility, Female (drug therapy, etiology)
• Ovulation Induction (methods)
• Pilot Projects
• Polycystic Ovary Syndrome (complications)
• Pregnancy
• Pregnancy Rate
• Prospective Studies